Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
因塞特(US:INCY) Businesswire·2025-12-07 14:30公司核心动态 - 公司旗下名为INCA033989的first-in-class单克隆抗体药物获得美国FDA授予的突破性疗法认定 [1] - 该药物靶向突变CALR [1] - 该新闻发布于美国血液学会年会背景下 [1] 产品管线进展 - 产品INCA033989是一种靶向突变CALR的单克隆抗体 [1] - 该产品属于first-in-class类别 [1]